A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report

Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164

Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects

In this case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment, Shao et al. sought to determine the efficacy and safety of ixekizumab as an alternative treatment.